Clinical Study

Hoosier Hcrn Gu17-295- A Phase II Trial Of Atezolizumab Plus Chemotherapy After Progression On Pd-1 Or Pd-L1 Inhibitor In Cisplatin-Ineligible Patients With Advanced Urothelial Carcinoma

Posted Date: Jul 8, 2020

  • Investigator: Shuchi Gulati
  • Specialties: Cancer, Oncology
  • Type of Study: Drug

The primary goal of this study is to Evaluate PFS among patients to be treated with atezolizumab in combination with carboplatin + gemcitabine or docetaxel, who have cisplatin-ineligible metastatic urothelial carcinoma and who have progressed on prior PD-1 or PD-L1 inhibitor.


To Be Eligible: Must Have Diagnosis Of Unresectable Locally Advanced Urothelial Carcinoma, Ecog 0-2, No Progressive Metastatic Disease After Previous Treatment With Pd-1 Or Pd-L1 Inhibitor, No Ae/Complication From Pd-1 Or Pd-L1 Inhibitor Requiring Permanent Discontinuation, No Other Malignancy Within 4 Years, No Active Or Recent Uncontrolled Infection Or Disorder That May Impact Treatment


Urothelial Cancer

For More Information:

Uc Cancer Center

  • This contact page is monitored Monday – Friday during business hours, 8 am to 5 pm EST. Do not rely on communication through this website for medical treatment or care. This website is not designed for such purposes.
    For questions regarding clinical studies at UC Health, contact us at or (513) 245-3417.